Figure 1. (A): Relative mRNA expression values of the genes ERCC1, ERCC2 and ERCC5 in a cohort of 26 patients with extended stage-SCLC compared to the healthy group. Values were normalized to the control group, value = 1. (B–G): Association between mRNA expression levels of the genes and age (< or ≥70 years) (B) (p = 0.49 for ERCC1, p = 0.47 for ERCC2, p = 0.32 for ERCC5), sex (C) (p = 0.47 for ERCC1, p = 0.54 for ERCC2, p = 0.81 for ERCC5), response to therapy (D) (p = 0.40 for ERCC1, p = 0.49 for ERCC2, p = 0.60 for ERCC5) and site of metastasis at diagnosis: brain (E) (p = 0.85 for ERCC1, p = 0.70 for ERCC2, p = 0.77 for ERCC5), liver (F) (p = 0.57 for ERCC1, p = 015 for ERCC2, p = 0.71 for ERCC5) and bone (G) (p = 0.32 for ERCC1, p = 0.83 for ERCC2, p = 0.34 for ERCC5).
